Dyslipidemia in patients with chronic kidney disease.

Abstract

Chronic kidney disease (CKD) is associated with high risk for cardiovascular disease (CVD). This association is multifactorial, but CKD is often associated with dyslipidemia, which likely contributes. Patients with CKD have dyslipidemia even at early stages of renal dysfunction and dyslipidemia tends to progress with deterioration of kidney function. The dyslipidemia in CKD is largely due to increased triglyceride levels, decreased HDL-C and varying levels of LDL-C. Current management of CKD may also affect lipid levels. Robust clinical trials demonstrate that statins are safe and efficacious in both lipid lowering and prevention of CVD events in pre-end stage CKD and post-transplant. However, there is no evidence of improved CVD outcomes with statin use in dialysis patients. This review will focus on mechanisms underlying dyslipidemia in CKD and clinical trial evidence for lipid lowering therapy in patients with CKD.

• Authors: Matthew R Hager, Archana D Narla, Lisa R Tannock
• Journal: Reviews in endocrine & metabolic disorders (Rev Endocr Metab Disord) Vol. 18 Issue 1 Pg. 29-40 (03 2017) ISSN: 1573-2606 [Electronic] Germany
• PMID: 28000009 (Publication Type: Journal Article, Review, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Hydroxymethylglutaryl-CoA Reductase Inhibitors

Topics

• Dyslipidemias (blood, drug therapy)
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Renal Insufficiency, Chronic (blood)